PET
Asset Logo

Phoslock Environmental Technologies Limited

🇦🇺 ASX

🔨 COMMERCIAL SERVICES & SUPPLIES

Compare
Add to watchlist
👑 Overview

📈 Performance

💵 Cost

🍃 Esg

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

-19.50%
Annual Growth

5 years average annual growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

5
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

Phoslock Environmental Technologies Ltd. is a global water technology company which engages in the manufacture and sale of environmental solutions. The firm is specialized in engineering solutions and water treatment products to remediate polluted lakes, rivers, canals and drinking water reservoirs. The company has four operating segments based on geographical areas, such as Australia/NZ, Europe/The United Kingdom, United States/Canada/Brazil, and China. The Company’s products include Phoslock and Phosflow. Phoslock is a proprietary water treatment product that permanently binds excess phosphorus in the water column and sediments and enables it to settle in an environmentally benign state. Along with Phoslock, the Company also supplies zeolites and specialized solutions that address water pollution issues. Phosflow absorbs phosphorus from water upon contact. Phosflow is used in wastewater effluents including municipal, industrial, and agricultural wastewaters. Phosflow can be packaged into various vessels and chambers, as well as water permeable containers.

📈 Performance

Price History

-40.18%

1M

10Y

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

N/A
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🍃 Environmental, Social and Governance scores ℹ️

🌳

Environmental Score
50

A measure of an organisations or investment's impact on the natural environment, including factors such as carbon emissions, resource usage, and pollution

🕊️

Social Score
33

An assessment of an organisations management practices, board structure, transparency, and accountability, reflecting its commitment to ethical behavior and responsible decision-making.

⚖️

Governance Score
41

An evaluation of an organisations impact on society, focusing on factors such as employee welfare, diversity and inclusion, community engagement, and product safety and quality.

🤓 Advanced information

Technical Info

💰 Price*

$0.03

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in PET

5

📊 Total Capital Earnings

N/A

🔃 Average investment frequency

N/A

💵 Average investment amount

N/A

Last time a customer invested in PET

147 days
PET investor breakdown
💵 Income of investors

More than 200k

150k - 200k

11%

100k - 150k

44%

50k - 100k

11%

Less than 50k

22%
👶 Age of investors

18 - 25

26 - 34

20%

35 - 90

80%
🙋 Legal gender of investors

Female

Male

100%

Pearlers who invest in PET also invest in...

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

🙌 Performance (5Yr p.a)

3.85%

📊 Share price

$100.90 AUD

⛳️ DIVERSIFIED

🇦🇺 AUSTRALIA

🧱 MATERIALS

💸 FINANCIALS

Find Out More

Australian Ethical Investment Ltd. engages in the provision of investment management services. The company is headquartered in Sydney, New South Wales. The company went IPO on 2002-12-17. The company is focused on future-building sectors, including renewable energy, information technology, healthcare, and education, and restrict+ investment in areas like fossil fuel companies, gambling and tobacco. The company creates well-diversified portfolios of ethical investments that can deliver long-term, risk-adjusted returns. All its superannuation, managed fund, pension and exchange traded fund products are ethically screened, and investment focused. Its managed funds use professional investment management alongside ethical considerations. The company offers a diverse range of super investment options depending on investment objective, timeframe and risk profile. Its Ethical Criteria apply to all portfolios it manages, including its pension options.

🙌 Performance (5Yr p.a)

9.55%

📊 Share price

$4.30 AUD

💸 FINANCIALS

🌳 ENVIRONMENTAL

📈 HIGH PRICE GROWTH

🕊️ SOCIALLY AWARE

ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.

🙌 Performance (5Yr p.a)

13.00%

📊 Share price

$15.13 AUD

🇦🇺 EX AUSTRALIA

📈 HIGH PRICE GROWTH

⛳️ DIVERSIFIED

🤖 TECHNOLOGY

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 6138.42m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

🙌 Performance (5Yr p.a)

4.31%

📊 Share price

$135.91 AUD

⛳️ DIVERSIFIED

💸 FINANCIALS

FAIR.AX was created on 2017-11-27 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes Australian companies that have passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.

🙌 Performance (5Yr p.a)

2.63%

📊 Share price

$20.56 AUD

🇦🇺 AUSTRALIA

💸 FINANCIALS

⛳️ DIVERSIFIED

Want more shares? Try these...

Peel Mining Ltd. engages in the exploration and development of precious, base, and specialty metals resources in New South Wales and Western Australia, Australia. The company is headquartered in Perth, Western Australia. The company went IPO on 2007-05-17. The firm is focused on exploration and development of its projects in the Cobar Region of New South Wales, Australia. The firm's projects include the Mallee Bull Project, Wirlong Project, May Day Project and Southern Nights / Wagga Tank. The Mallee Bull Copper Project is located approximately 100 kilometers (km) south of Cobar in western New South Wales (NSW) and is situated on a 20,000-acre pastoral lease owned by Peel Mining. The Wirlong Project is located over 75 km south of Cobar and 30 km southwest of Nymagee, NSW. The May Day Pit is located approximately 105km south-southeast of Cobar in western NSW. The Southern Nights / Wagga Tank project can be divided into two prospects: Wagga Tank to the North and Southern Nights over one km to the South. They are located over 130 km south of Cobar and 30 km northwest of Mount Hope in central NSW.

🙌 Performance (5Yr p.a)

-11.38%

📊 Share price

$0.13 AUD

⛏️ MINING

Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.

🙌 Performance (5Yr p.a)

-4.40%

📊 Share price

$0.08 AUD

📦 LOGISTICS

Compare
Add to watchlist